AHL Partners’s Aerie Pharmaceuticals AERI Stock Holding History

AHL Partners’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-6,932	Closed	-$337K	–	1403
2017 Q3	$337K	Buy	+6,932	New	+$378K	0.01%	1133

Other funds holding AERI

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AHL Partners's AERI Position: Q4 2017 in Review

AHL Partners sold out of Aerie Pharmaceuticals (AERI) in Q4 2017, closing a stake of 6,932 shares — an estimated $337K sold.

AHL Partners first reported a position in AERI in Q3 2017 and held it in 1 quarter. The position peaked at $337K in Q3 2017. 179 funds tracked by Wall St. Rank hold AERI as of Q4 2017.

AHL Partners reported no remaining Aerie Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
AHL Partners sold 6,932 Aerie Pharmaceuticals shares in Q4 2017, an estimated $337K.
AHL Partners first reported a position in Aerie Pharmaceuticals in Q3 2017 and held it in 1 quarter.
AHL Partners's Aerie Pharmaceuticals position peaked at $337K in Q3 2017.
179 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2017.

Based on AHL Partners's 13F filing for Q4 2017, filed 14 Feb 2018.